Frontiers of Medicine最新文献_第8页

Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma. CD39 在 GPC3-CAR-T 细胞中的适度表达显示出对肝细胞癌的高疗效。

IF 3.9 3区医学

Frontiers of Medicine Pub Date : 2024-08-01 Epub Date: 2024-06-04 DOI: 10.1007/s11684-024-1071-9

Fan Zou, Jialiang Wei, Jialang Zhuang, Yafang Liu, Jizhou Tan, Xianzhang Huang, Ting Liu

{"title":"Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma.","authors":"Fan Zou, Jialiang Wei, Jialang Zhuang, Yafang Liu, Jizhou Tan, Xianzhang Huang, Ting Liu","doi":"10.1007/s11684-024-1071-9","DOIUrl":"10.1007/s11684-024-1071-9","url":null,"abstract":"CD39 serves as a crucial biomarker for neoantigen-specific CD8+ T cells and is associated with antitumor activity and exhaustion. However, the relationship between CD39 expression levels and the function of chimeric antigen receptor T (CAR-T) cells remains controversial. This study aimed to investigate the role of CD39 in the functional performance of CAR-T cells against hepatocellular carcinoma (HCC) and explore the therapeutic potential of CD39 modulators, such as mitochondrial division inhibitor-1 (mdivi-1), or knockdown CD39 through short hairpin RNA. Our findings demonstrated that glypican-3-CAR-T cells with moderate CD39 expression exhibited a strong antitumor activity, while high and low levels of CD39 led to an impaired cellular function. Methods modulating the proportion of CD39 intermediate (CD39int)-phenotype CAR-T cells such as mdivi-1 and CD39 knockdown enhanced and impaired T cell function, respectively. The combination of mdivi-1 and CD39 knockdown in CAR-T cells yielded the highest proportion of infiltrated CD39int CAR-T cells and demonstrated a robust antitumor activity in vivo. In conclusion, this study revealed the crucial role of CD39 in CAR-T cell function, demonstrated the potential therapeutic efficacy of combining mdivi-1 with CD39 knockdown in HCC, and provided a novel treatment strategy for HCC patients in the field of cellular immunotherapy.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"708-720"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141237292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of acupuncture in refractory irritable bowel syndrome patients: a randomized controlled trial. 针灸对难治性肠易激综合征患者的疗效：随机对照试验。

IF 3.9 3区医学

Frontiers of Medicine Pub Date : 2024-08-01 Epub Date: 2024-07-03 DOI: 10.1007/s11684-024-1073-7

Jun Zhao, Hui Zheng, Xin Wang, Xuefei Wang, Yunzhou Shi, Chaorong Xie, Qingfeng Tao, Da Li, Jingwen Sun, Junjian Tian, Junxia Gao, Huimin Liu, Suhua Shi, Jinxia Ni, Rongdan Xue, Hui Hu, Min Chen, Shuguang Yu, Zhigang Li

{"title":"Efficacy of acupuncture in refractory irritable bowel syndrome patients: a randomized controlled trial.","authors":"Jun Zhao, Hui Zheng, Xin Wang, Xuefei Wang, Yunzhou Shi, Chaorong Xie, Qingfeng Tao, Da Li, Jingwen Sun, Junjian Tian, Junxia Gao, Huimin Liu, Suhua Shi, Jinxia Ni, Rongdan Xue, Hui Hu, Min Chen, Shuguang Yu, Zhigang Li","doi":"10.1007/s11684-024-1073-7","DOIUrl":"10.1007/s11684-024-1073-7","url":null,"abstract":"Previous studies have confirmed that acupuncture for irritable bowel syndrome (IBS) provided an additional benefit over usual care alone. Therefore, we performed a multicenter, randomized, sham-controlled trial to assess the efficacy and safety of acupuncture versus sham acupuncture for refractory IBS in patients in the context of conventional treatments. Patients in the acupuncture and sham acupuncture groups received real or sham acupuncture treatment in 3 sessions per week for a total of 12 sessions. The primary outcome was a change in the IBS-Symptom Severity Scale (IBS-SSS) score from baseline to week 4. A total of 521 participants were screened, and 170 patients (85 patients per group) were enrolled and included in the intention-to-treat analysis. Baseline characteristics were comparable across the two groups. From baseline to 4 weeks, the IBS-SSS total score decreased by 140.0 (95% CI: 126.0 to 153.9) in the acupuncture group and 64.4 (95% CI: 50.4 to 78.3) in the sham acupuncture group. The between-group difference was 75.6 (95% CI: 55.8 to 95.4). Acupuncture efficacy was maintained during the 4-week follow-up period. There were no serious adverse events. In conclusion, acupuncture provided benefits when combined with treatment as usual, providing more options for the treatment of refractory IBS.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"678-689"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transparency and reporting characteristics of randomized controlled trials with Chinese herbal medicine formulas interventions. 中药配方干预随机对照试验的透明度和报告特点。

IF 3.9 3区医学

Frontiers of Medicine Pub Date : 2024-08-01 Epub Date: 2024-07-23 DOI: 10.1007/s11684-024-1092-4

Juan Wang, Dongni Shi, Yaochen Wang, Xuanqi Zhang, Han Li, Xihong Wang, Shufeng Luo, Lihan Hu, Jiashuai Deng, Lin Zhang, Chung Tai Lau, Chung Wah Cheng, Fei Han, Ji Li, Ping Wang, Aiping Lyu, Zhaoxiang Bian, Xuan Zhang

引用次数: 0

Epigenetic silencing of BEND4, a novel DNA damage repair gene, is a synthetic lethal marker for ATM inhibitor in pancreatic cancer. 新型DNA损伤修复基因BEND4的表观遗传沉默是胰腺癌ATM抑制剂的合成致死标志。

IF 3.9 3区医学

Frontiers of Medicine Pub Date : 2024-08-01 Epub Date: 2024-06-27 DOI: 10.1007/s11684-023-1053-3

Yuanxin Yao, Honghui Lv, Meiying Zhang, Yuan Li, James G Herman, Malcolm V Brock, Aiai Gao, Qian Wang, Francois Fuks, Lirong Zhang, Mingzhou Guo

{"title":"Epigenetic silencing of BEND4, a novel DNA damage repair gene, is a synthetic lethal marker for ATM inhibitor in pancreatic cancer.","authors":"Yuanxin Yao, Honghui Lv, Meiying Zhang, Yuan Li, James G Herman, Malcolm V Brock, Aiai Gao, Qian Wang, Francois Fuks, Lirong Zhang, Mingzhou Guo","doi":"10.1007/s11684-023-1053-3","DOIUrl":"10.1007/s11684-023-1053-3","url":null,"abstract":"Synthetic lethality is a novel model for cancer therapy. To understand the function and mechanism of BEN domain-containing protein 4 (BEND4) in pancreatic cancer, eight cell lines and a total of 492 cases of pancreatic neoplasia samples were included in this study. Methylation-specific polymerase chain reaction, CRISPR/Cas9, immunoprecipitation assay, comet assay, and xenograft mouse model were used. BEND4 is a new member of the BEN domain family. The expression of BEND4 is regulated by promoter region methylation. It is methylated in 58.1% (176/303) of pancreatic ductal adenocarcinoma (PDAC), 33.3% (14/42) of intraductal papillary mucinous neoplasm, 31.0% (13/42) of pancreatic neuroendocrine tumor, 14.3% (3/21) of mucinous cystic neoplasm, 4.3% (2/47) of solid pseudopapillary neoplasm, and 2.7% (1/37) of serous cystic neoplasm. BEND4 methylation is significantly associated with late-onset PDAC (> 50 years, P < 0.01) and tumor differentiation (P < 0.0001), and methylation of BEND4 is an independent poor prognostic marker (P < 0.01) in PDAC. Furthermore, BEND4 plays tumor-suppressive roles in vitro and in vivo. Mechanistically, BEND4 involves non-homologous end joining signaling by interacting with Ku80 and promotes DNA damage repair. Loss of BEND4 increased the sensitivity of PDAC cells to ATM inhibitor. Collectively, the present study revealed an uncharacterized tumor suppressor BEND4 and indicated that methylation of BEND4 may serve as a potential synthetic lethal marker for ATM inhibitor in PDAC treatment.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"721-734"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141456285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

lncRNA Gm20257 alleviates pathological cardiac hypertrophy by modulating the PGC-1α-mitochondrial complex IV axis. lncRNA Gm20257通过调节PGC-1α-线粒体复合物IV轴减轻病理性心肌肥厚

IF 3.9 3区医学

Frontiers of Medicine Pub Date : 2024-08-01 Epub Date: 2024-06-27 DOI: 10.1007/s11684-024-1065-7

Tong Yu, Qiang Gao, Guofang Zhang, Tianyu Li, Xiaoshan Liu, Chao Li, Lan Zheng, Xiang Sun, Jianbo Wu, Huiying Cao, Fangfang Bi, Ruifeng Wang, Haihai Liang, Xuelian Li, Yuhong Zhou, Lifang Lv, Hongli Shan

{"title":"lncRNA Gm20257 alleviates pathological cardiac hypertrophy by modulating the PGC-1α-mitochondrial complex IV axis.","authors":"Tong Yu, Qiang Gao, Guofang Zhang, Tianyu Li, Xiaoshan Liu, Chao Li, Lan Zheng, Xiang Sun, Jianbo Wu, Huiying Cao, Fangfang Bi, Ruifeng Wang, Haihai Liang, Xuelian Li, Yuhong Zhou, Lifang Lv, Hongli Shan","doi":"10.1007/s11684-024-1065-7","DOIUrl":"10.1007/s11684-024-1065-7","url":null,"abstract":"Pathological cardiac hypertrophy, a major contributor to heart failure, is closely linked to mitochondrial function. The roles of long noncoding RNAs (lncRNAs), which regulate mitochondrial function, remain largely unexplored in this context. Herein, a previously unknown lncRNA, Gm20257, was identified. It markedly increased under hypertrophic stress in vivo and in vitro. The suppression of Gm20257 by using small interfering RNAs significantly induced cardiomyocyte hypertrophy. Conversely, the overexpression of Gm20257 through plasmid transfection or adeno-associated viral vector-9 mitigated angiotensin II-induced hypertrophic phenotypes in neonatal mouse ventricular cells or alleviated cardiac hypertrophy in a mouse TAC model respectively, thus restoring cardiac function. Importantly, Gm20257 restored mitochondrial complex IV level and enhanced mitochondrial function. Bioinformatics prediction showed that Gm20257 had a high binding score with peroxisome proliferator-activated receptor coactivator-1 (PGC-1α), which could increase mitochondrial complex IV. Subsequently, Western blot analysis results revealed that Gm20257 substantially affected the expression of PGC-1α. Further analyses through RNA immunoprecipitation and immunoblotting following RNA pull-down indicated that PGC-1α was a direct downstream target of Gm20257. This interaction was demonstrated to rescue the reduction of mitochondrial complex IV induced by hypertrophic stress and promote the generation of mitochondrial ATP. These findings suggest that Gm20257 improves mitochondrial function through the PGC-1α-mitochondrial complex IV axis, offering a novel approach for attenuating pathological cardiac hypertrophy.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"664-677"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141456286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single-cell RNA-seq reveals the transcriptional program underlying tumor progression and metastasis in neuroblastoma. 单细胞 RNA 序列分析揭示了神经母细胞瘤肿瘤进展和转移的转录程序。

IF 3.9 3区医学

Frontiers of Medicine Pub Date : 2024-08-01 Epub Date: 2024-07-17 DOI: 10.1007/s11684-024-1081-7

Zhe Nian, Dan Wang, Hao Wang, Wenxu Liu, Zhenyi Ma, Jie Yan, Yanna Cao, Jie Li, Qiang Zhao, Zhe Liu

{"title":"Single-cell RNA-seq reveals the transcriptional program underlying tumor progression and metastasis in neuroblastoma.","authors":"Zhe Nian, Dan Wang, Hao Wang, Wenxu Liu, Zhenyi Ma, Jie Yan, Yanna Cao, Jie Li, Qiang Zhao, Zhe Liu","doi":"10.1007/s11684-024-1081-7","DOIUrl":"10.1007/s11684-024-1081-7","url":null,"abstract":"Neuroblastoma (NB) is one of the most common childhood malignancies. Sixty percent of patients present with widely disseminated clinical signs at diagnosis and exhibit poor outcomes. However, the molecular mechanisms triggering NB metastasis remain largely uncharacterized. In this study, we generated a transcriptomic atlas of 15 447 NB cells from eight NB samples, including paired samples of primary tumors and bone marrow metastases. We used time-resolved analysis to chart the evolutionary trajectory of NB cells from the primary tumor to the metastases in the same patient and identified a common 'starter' subpopulation that initiates tumor development and metastasis. The 'starter' population exhibited high expression levels of multiple cell cycle-related genes, indicating the important role of cell cycle upregulation in NB tumor progression. In addition, our evolutionary trajectory analysis demonstrated the involvement of partial epithelial-to-mesenchymal transition (p-EMT) along the metastatic route from the primary site to the bone marrow. Our study provides insights into the program driving NB metastasis and presents a signature of metastasis-initiating cells as an independent prognostic indicator and potential therapeutic target to inhibit the initiation of NB metastasis.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"690-707"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Echocardiographic Measurements in Normal Chinese Adults (EMINCA) II focusing on left ventricular and left atrial size and function by three-dimensional echocardiography. 中国正常成人超声心动图测量（EMINCA）II》侧重于通过三维超声心动图测量左心室和左心房的大小和功能。

IF 3.9 3区医学

Frontiers of Medicine Pub Date : 2024-08-01 Epub Date: 2024-05-18 DOI: 10.1007/s11684-023-1045-3

Yingbin Wang, Yu Zhang, Guihua Yao, Hong Tang, Lixin Chen, Lixue Yin, Tiangang Zhu, Jianjun Yuan, Wei Han, Jun Yang, Xianhong Shu, Ya Yang, Yulin Wei, Yanli Guo, Weidong Ren, Dongmei Gao, Guilin Lu, Ji Wu, Hongning Yin, Yuming Mu, Jiawei Tian, Lijun Yuan, Xiaojing Ma, Hongyan Dai, Yunchuan Ding, Mingyan Ding, Qing Zhou, Hao Wang, Di Xu, Mei Zhang, Yun Zhang

{"title":"Echocardiographic Measurements in Normal Chinese Adults (EMINCA) II focusing on left ventricular and left atrial size and function by three-dimensional echocardiography.","authors":"Yingbin Wang, Yu Zhang, Guihua Yao, Hong Tang, Lixin Chen, Lixue Yin, Tiangang Zhu, Jianjun Yuan, Wei Han, Jun Yang, Xianhong Shu, Ya Yang, Yulin Wei, Yanli Guo, Weidong Ren, Dongmei Gao, Guilin Lu, Ji Wu, Hongning Yin, Yuming Mu, Jiawei Tian, Lijun Yuan, Xiaojing Ma, Hongyan Dai, Yunchuan Ding, Mingyan Ding, Qing Zhou, Hao Wang, Di Xu, Mei Zhang, Yun Zhang","doi":"10.1007/s11684-023-1045-3","DOIUrl":"10.1007/s11684-023-1045-3","url":null,"abstract":"Current guidelines encourage large studies in a diverse population to establish normal reference ranges for three-dimensional (3D) echocardiography for different ethnic groups. This study was designed to establish the normal values of 3D-left ventricular (LV) and left atrial (LA) volume and function in a nationwide, population-based cohort of healthy Han Chinese adults. A total of 1117 healthy volunteers aged 18-89 years were enrolled from 28 collaborating laboratories in China. Two sets of 3D echocardiographic instruments were used, and full-volume echocardiographic images were recorded and transmitted to a core laboratory for image analysis with a vendor-independent off-line workstation. Finally, 866 volunteers (mean age of 48.4 years, 402 men) were qualified for final analysis. Most parameters exhibited substantial differences between different sex and age groups, even after indexation by body surface area. The normal ranges of 3D-LV and 3D-LA volume and function differed from those recommended by the American Society of Echocardiography and the European Association of Cardiovascular Imaging guidelines, presented by the World Alliance Societies of Echocardiography (WASE) study, and from the 2D values in the EMINCA study. The normal reference values of 3D echocardiography-derived LV and LA volume and function were established for the first time in healthy Han Chinese adults. Normal ranges of 3D-LV and 3D-LA echocardiographic measurements stratified with sex, age, and race should be recommended for clinical applications.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"649-663"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140957061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epigenetics and environmental health. 表观遗传学与环境健康。

IF 3.9 3区医学

Frontiers of Medicine Pub Date : 2024-08-01 Epub Date: 2024-05-28 DOI: 10.1007/s11684-023-1038-2

Min Zhang, Ting Hu, Tianyu Ma, Wei Huang, Yan Wang

{"title":"Epigenetics and environmental health.","authors":"Min Zhang, Ting Hu, Tianyu Ma, Wei Huang, Yan Wang","doi":"10.1007/s11684-023-1038-2","DOIUrl":"10.1007/s11684-023-1038-2","url":null,"abstract":"Epigenetic modifications including DNA methylation, histone modifications, chromatin remodeling, and RNA modifications complicate gene regulation and heredity and profoundly impact various physiological and pathological processes. In recent years, accumulating evidence indicates that epigenetics is vulnerable to environmental changes and regulates the growth, development, and diseases of individuals by affecting chromatin activity and regulating gene expression. Environmental exposure or induced epigenetic changes can regulate the state of development and lead to developmental disorders, aging, cardiovascular disease, Alzheimer's disease, cancers, and so on. However, epigenetic modifications are reversible. The use of specific epigenetic inhibitors targeting epigenetic changes in response to environmental exposure is useful in disease therapy. Here, we provide an overview of the role of epigenetics in various diseases. Furthermore, we summarize the mechanism of epigenetic alterations induced by different environmental exposures, the influence of different environmental exposures, and the crosstalk between environmental variation epigenetics, and genes that are implicated in the body's health. However, the interaction of multiple factors and epigenetics in regulating the initiation and progression of various diseases complicates clinical treatments. We discuss some commonly used epigenetic drugs targeting epigenetic modifications and methods to prevent or relieve various diseases regulated by environmental exposure and epigenetics through diet.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"571-596"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141161407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking the potential of bispecific ADCs for targeted cancer therapy. 释放双特异性 ADC 在癌症靶向治疗中的潜力。

IF 3.9 3区医学

Frontiers of Medicine Pub Date : 2024-08-01 Epub Date: 2024-07-23 DOI: 10.1007/s11684-024-1072-8

Hongye Zeng, Wenjing Ning, Xue Liu, Wenxin Luo, Ningshao Xia

引用次数: 0

Regulations of m⁶A and other RNA modifications and their roles in cancer. m6A 和其他 RNA 修饰的调节及其在癌症中的作用。

IF 3.9 3区医学

Frontiers of Medicine Pub Date : 2024-08-01 Epub Date: 2024-06-22 DOI: 10.1007/s11684-024-1064-8

Xin-Hui Chen, Kun-Xiong Guo, Jing Li, Shu-Hui Xu, Huifang Zhu, Guang-Rong Yan

{"title":"Regulations of m6A and other RNA modifications and their roles in cancer.","authors":"Xin-Hui Chen, Kun-Xiong Guo, Jing Li, Shu-Hui Xu, Huifang Zhu, Guang-Rong Yan","doi":"10.1007/s11684-024-1064-8","DOIUrl":"10.1007/s11684-024-1064-8","url":null,"abstract":"RNA modification is an essential component of the epitranscriptome, regulating RNA metabolism and cellular functions. Several types of RNA modifications have been identified to date; they include N6-methyladenosine (m6A), N1-methyladenosine (m1A), 5-methylcytosine (m5C), N7-methylguanosine (m7G), N6,2'-O-dimethyladenosine (m6Am), N4-acetylcytidine (ac4C), etc. RNA modifications, mediated by regulators including writers, erasers, and readers, are associated with carcinogenesis, tumor microenvironment, metabolic reprogramming, immunosuppression, immunotherapy, chemotherapy, etc. A novel perspective indicates that regulatory subunits and post-translational modifications (PTMs) are involved in the regulation of writer, eraser, and reader functions in mediating RNA modifications, tumorigenesis, and anticancer therapy. In this review, we summarize the advances made in the knowledge of different RNA modifications (especially m6A) and focus on RNA modification regulators with functions modulated by a series of factors in cancer, including regulatory subunits (proteins, noncoding RNA or peptides encoded by long noncoding RNA) and PTMs (acetylation, SUMOylation, lactylation, phosphorylation, etc.). We also delineate the relationship between RNA modification regulator functions and carcinogenesis or cancer progression. Additionally, inhibitors that target RNA modification regulators for anticancer therapy and their synergistic effect combined with immunotherapy or chemotherapy are discussed.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"622-648"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0